RTP Mobile Logo
Year in Review — Proceedings from a Multitumor Regional Symposium Focused on the Application of Emerging Research Information to the Care of Patients with Common Cancers | Orlando, FL
Released January 2020

Proceedings from a daylong symposium, recorded in October 2019, Orlando, Florida, featuring key clinical presentations and papers in acute leukemias, breast cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, lung cancer and lymphomas and chronic lymphocytic leukemia. Including perspectives from Drs Jeremy Abramson, Johanna Bendell, Michael J Birrer, Julie R Brahmer, Courtney D DiNardo, J Randolph Hecht, Mark Levis, Ursula Matulonis, Craig Moskowitz, Joel W Neal, Eileen M O’Reilly, Joyce O’Shaughnessy, Mark D Pegram, Daniel P Petrylak, David I Quinn and Mitchell R Smith. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This educational activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows and other allied cancer professionals.

    OVERVIEW OF ACTIVITY
    Clinical controversies and uncertainties persist in the management of all common cancers, and thousands of ongoing research trials worldwide attempt to provide new answers to long-standing questions. As these trials reach maturity, clinical investigators initially present new data in abridged format at large scientific conferences and subsequently in full data sets formally published as part of peer-reviewed journals. Today, numerous annual oncology conferences release new clinical data and hundreds of peer-reviewed publications feature articles related to cancer research, treatment and practical management. The extensive list of available treatment options poses a challenge to the practicing clinician who must maintain knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors.

    These proceedings from a daylong symposium combine the perspectives of 16 renowned investigators with a review of key recent presentations and publications across acute leukemias, breast cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, lung cancer and lymphomas and chronic lymphocytic leukemia to assist medical oncologists, hematologists, hematology-oncology fellows and other allied cancer professionals in the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Effectively apply the results of practice-changing clinical research to the care of patients with breast, gastrointestinal, genitourinary, gynecologic, lung and select hematologic cancers.
    • Appraise the clinical relevance of recent pivotal cancer research results published in peer-reviewed journals and/or presented at major oncology conferences.
    • Recall ongoing trials in breast, gastrointestinal, genitourinary, gynecologic, lung and select hematologic cancers, and refer appropriate patients for study participation.
    • Incorporate clinical characteristics, logistical factors, tumor biomarkers and single and multigene signatures to individualize the care of patients with cancer.
    • Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
    • Refine or validate existing cancer treatment algorithms based on exposure to new data sets and the perspectives of tumor-specific clinical investigators.
    • Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider the implications for clinical practice.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Research To Practice designates this enduring material for a maximum of 7 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for this activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/YIRMultitumor19/CME.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Jeremy Abramson, MD
    Director, Center for Lymphoma
    Massachusetts General Hospital
    Associate Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Consulting Agreements: AbbVie Inc, Celgene Corporation, EMD Serono Inc, Genentech, Janssen Biotech Inc, Roche Laboratories Inc; Contracted Research: Celgene Corporation, Seattle Genetics.

    Johanna Bendell, MD
    Chief Development Officer
    Director, Drug Development Unit Nashville
    Sarah Cannon Research Institute
    Tennessee Oncology
    Nashville, Tennessee

    Consulting Agreements: Agios Pharmaceuticals Inc, Amgen Inc, Apexigen, Arch Oncology, ARMO BioSciences, Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Continuum Clinical, Cyteir Therapeutics, Daiichi Sankyo Inc, Five Prime Therapeutics Inc, FORMA Therapeutics, Genentech, Gilead Sciences Inc, GlaxoSmithKline, Incyte Corporation, Innate Pharma, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Leap Therapeutics Inc, Lilly, MacroGenics Inc, Merck, Merrimack Pharmaceuticals Inc, Moderna Inc, Molecular Partners, Novartis, OncoGenex Pharmaceuticals Inc, OncoMed Pharmaceuticals Inc, Pfizer Inc, PhoenixBio, Prelude Therapeutics, Roche Laboratories Inc, Sanofi Genzyme, Seattle Genetics, Taiho Oncology Inc, Tanabe Research Laboratories, TG Therapeutics Inc, Tizona Therapeutics Inc, Tolero Pharmaceuticals, Torque Therapeutics, Translational Drug Development; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, ADC Therapeutics SA, Agios Pharmaceuticals Inc, Amgen Inc, Apexigen, Arch Oncology, Arcus Biosciences, ARMO BioSciences, Array BioPharma Inc, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bellicum Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Calithera Biosciences, Celgene Corporation, Celldex Therapeutics, CytomX Therapeutics, Daiichi Sankyo Inc, eFFECTOR Therapeutics Inc, Eisai Inc, EMD Serono Inc, Evelo Biosciences Inc, Five Prime Therapeutics Inc, FORMA Therapeutics, Forty Seven Inc, Genentech, Gilead Sciences Inc, GlaxoSmithKline, Gossamer Bio, Harpoon Therapeutics, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Innate Pharma, Ipsen Biopharmaceuticals Inc, Jacobio Pharmaceuticals Co Ltd, Kolltan Pharmaceuticals Inc, Leap Therapeutics Inc, Lilly, MacroGenics Inc, MEI Pharma Inc, Merck, Merrimack Pharmaceuticals Inc, Mersana Therapeutics, Merus BV, Nektar, Novartis, Novocure, OncoGenex Pharmaceuticals Inc, OncoMed Pharmaceuticals Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pieris Pharmaceuticals Inc, Prelude Therapeutics, Rgenix, Roche Laboratories Inc, Sanofi Genzyme, Seattle Genetics, Shattuck Labs, Sierra Oncology, SynDevRx Inc, Taiho Oncology Inc, Takeda Oncology, Tarveda Therapeutics, Tempest Therapeutics Inc, TG Therapeutics Inc, TRACON Pharmaceuticals Inc, Tyrogenex Inc, Unum Therapeutics, Vyriad; Data and Safety Monitoring Board/Committee: Five Prime Therapeutics Inc.

    Michael J Birrer, MD, PhD
    Professor of Medicine/Hematology and Oncology
    Evalina B Spencer Chair in Oncology
    The University of Alabama at Birmingham
    Birmingham, Alabama

    No relevant conflicts of interest to disclose.

    Julie R Brahmer, MD
    Director, Thoracic Oncology Program
    Director, Johns Hopkins Kimmel Cancer Center at Bayview
    Professor of Oncology
    The Sidney Kimmel Comprehensive Cancer Center
    Johns Hopkins Medicine
    Baltimore, Maryland

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, Lilly, Merck, Roche Laboratories Inc, Syndax Pharmaceuticals Inc; Contracted Research: Bristol-Myers Squibb Company; Data and Safety Monitoring Board/Committee: GlaxoSmithKline.

    Courtney D DiNardo, MD, MSCE
    Associate Professor, Department of Leukemia
    Division of Cancer Medicine
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee: Jazz Pharmaceuticals Inc; Consulting Agreements: AbbVie Inc, Agios Pharmaceuticals Inc, Celgene Corporation, Daiichi Sankyo Inc, Notable.

    J Randolph Hecht, MD
    Professor of Clinical Medicine
    Director, UCLA GI Oncology Program
    Carol and Saul Rosenzweig Chair in Cancer Therapies Development
    Santa Monica, California

    Advisory Committee: Gritstone Oncology, Merck; Consulting Agreement: Amgen Inc; Contracted Research: AbbVie Inc, Advaxis Inc, Astellas, Halozyme Inc, Merck, Novartis.

    Mark Levis, MD, PhD
    Director, Adult Leukemia Program
    Co-Division Director, Hematologic Malignancies
    Professor of Oncology
    The Sidney Kimmel Comprehensive Cancer Center
    Johns Hopkins Medicine
    Baltimore, Maryland

    Advisory Committee: Agios Pharmaceuticals Inc, Amgen Inc, Astellas, Daiichi Sankyo Inc, FUJIFILM Pharmaceuticals USA Inc, Menarini Group, Novartis; Contracted Research: Astellas, FUJIFILM Pharmaceuticals USA Inc, Novartis; Data and Safety Monitoring Board/Committee: Astex Pharmaceuticals.

    Ursula Matulonis, MD
    Chief, Division of Gynecologic Oncology
    Brock-Wilson Family Chair
    Dana-Farber Cancer Institute
    Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Advisory Committee and Consulting Agreement: Novartis.

    Craig Moskowitz, MD
    Physician in Chief, Oncology Service Line
    Sylvester Comprehensive Cancer Center
    Professor of Medicine, Miller School of Medicine
    University of Miami Health System
    Don Soffer Clinical Research Center
    Miami, Florida

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Merck, Seattle Genetics, Takeda Oncology; Contracted Research: ADC Therapeutics SA, AstraZeneca Pharmaceuticals LP, Merck, Seattle Genetics.

    Joel W Neal, MD, PhD
    Assistant Professor of Medicine
    Division of Oncology
    Stanford Cancer Institute
    Stanford University
    Stanford, California

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Exelixis Inc, Genentech, Jounce Therapeutics Inc, Lilly, Roche Laboratories Inc, Takeda Oncology; Contracted Research: Adaptimmune, Boehringer Ingelheim Pharmaceuticals Inc, Exelixis Inc, Genentech, GlaxoSmithKline, Merck, Nektar, Novartis, Roche Laboratories Inc, Takeda Oncology.

    Eileen M O’Reilly, MD
    Winthrop Rockefeller Chair in Medical Oncology
    Section Head, Hepatopancreaticobiliary/Neuroendocrine Cancers
    Gastrointestinal Oncology Service
    Associate Director
    David M Rubenstein Center for Pancreatic Cancer
    Attending Physician, Member
    Memorial Sloan Kettering Cancer Center
    Professor of Medicine
    Weill Cornell Medical College
    New York, New York

    Consulting Agreements: Agios Pharmaceuticals Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, CytomX Therapeutics, Daiichi Sankyo Inc, Eisai Inc, Exelixis Inc, Halozyme Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Merck, Pfizer Inc, Sanofi Genzyme; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, Halozyme Inc, Incyte Corporation, Lilly, Novartis.

    Joyce O’Shaughnessy, MD
    Celebrating Women Chair in Breast Cancer Research
    Baylor University Medical Center
    Director, Breast Cancer Research Program
    Texas Oncology
    US Oncology
    Dallas, Texas

    Advisory Committee and Consulting Agreements: AbbVie Inc, Agendia Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, Genentech, Genomic Health Inc, GRAIL, Halozyme Inc, Heron Therapeutics, Immunomedics Inc, Ipsen Biopharmaceuticals Inc, Jounce Therapeutics, Lilly, Merck, Myriad Genetic Laboratories Inc, Novartis, Odonate Therapeutics, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc, Seattle Genetics, Syndax Pharmaceuticals Inc.

    Mark D Pegram, MD
    Susy Yuan-Huey Hung Professor of Medicine
    Director of the Breast Oncology Program
    Associate Dean, Clinical Research Quality
    Associate Director for Clinical Research
    Stanford Cancer Institute
    Stanford University School of Medicine
    Stanford, California

    Advisory Committee and Consulting Agreements: Genentech, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc, Samsung Bioepis.

    Daniel P Petrylak, MD
    Professor of Internal Medicine (Medical Oncology) and Urology
    Yale University
    New Haven, Connecticut

    Consulting Agreements: Advanced Accelerator Applications, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Clovis Oncology, Exelixis Inc, Incyte Corporation, Janssen Biotech Inc, Lilly, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Seattle Genetics, UroGen Pharma; Contracted Research: Advanced Accelerator Applications, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Clovis Oncology, Endocyte Inc, Genentech, Innocrin Pharmaceuticals Inc, Lilly, Merck, Novartis, Pfizer Inc, Progenics Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi Genzyme, Seattle Genetics; Ownership Interest: Bellicum Pharmaceuticals Inc, Tyme Inc.

    David I Quinn, MBBS, PhD
    Medical Director, Norris Cancer Hospital and Clinics
    Head, GU Cancer Section
    Division of Cancer Medicine and Blood Diseases
    USC Norris Comprehensive Cancer Center
    Los Angeles, California

    Advisory Committee and Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Dendreon Pharmaceuticals Inc, Exelixis Inc, Genentech, Janssen Biotech Inc, Merck, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Sanofi Genzyme, Seattle Genetics; Contracted Research: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech, Merck, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Seattle Genetics; Data and Safety Monitoring Board/Committee: Children’s Hospital Los Angeles, Eisai Inc, US Biotest Inc.

    Mitchell R Smith, MD, PhD
    Professor of Medicine
    Associate Center Director for Clinical Investigations
    Director, Division of Hematology and Oncology
    GW Cancer Center
    Washington, DC

    Data and Safety Monitoring Board/Committee: Eastern Cooperative Oncology Group; Speakers Bureau: AstraZeneca Pharmaceuticals LP, EUSA Pharma.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Adaptive Biotechnologies, Amgen Inc, Array BioPharma Inc, Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boston Biomedical Inc and Tolero Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Exelixis Inc, Genentech, Genomic Health Inc, Gilead Sciences Inc, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Sanofi Genzyme, Seattle Genetics, Taiho Oncology Inc, Takeda Oncology, and Tesaro, A GSK Company.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: January 2020
    Expiration date: January 2021

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):